Orthofix Medical, Inc. (OFIX)

Orthofix Medical Inc.'s stock has experienced fluctuations, trading at $13.03 as of February 2, 2026, with a 52-week range between $10.24 and $20.48. The stock saw a decline of 22.50% between January 17, 2025, and January 16, 2026. The Q3 2025 earnings report on November 4, 2025, reported an EPS of -$0.57, missing analysts' forecasts, but revenue beat expectations at $203.4 million. Despite the earnings miss, the company reported seven consecutive quarters of EBITDA margin expansion. Analyst coverage includes TD Cowen initiating coverage with a "Hold" recommendation, Barrington Research maintaining an "Outperform" recommendation, and Stifel reiterating a "Buy" recommendation. The consensus rating from analysts is "Hold," with an average price target of $20.00.

Orthofix Medical Inc. experiences demand seasonality for its products and services. The company anticipates a meaningful increase in revenue during the fourth quarter due to typical seasonality patterns. This seasonality is also influenced by the deployment of a significant number of spinal implant sets later in the third quarter, contributing to the expected fourth-quarter increase.

Orthofix Medical Inc. is a global medical technology company specializing in musculoskeletal disorder solutions, operating in the orthopedic and spine care markets through its Global Spine and Global Orthopedics segments. The Global Spine segment offers products for spinal fusion, motion preservation, and bone growth stimulation, including non-invasive bone growth stimulators, spinal implants, biologics, motion preservation devices, and navigation technologies. The Global Orthopedics segment provides products for trauma, limb reconstruction, and pediatric orthopedics, including external and internal fixation orthopedic products, regenerative products, tissue forms, fracture management, and foot and ankle products.

Orthofix Medical Inc. operates in over 70 countries with a strong presence across North America, Europe, and Asia-Pacific. The company has facilities in the United States, the United Kingdom, Brazil, Italy, France, and Germany. Orthofix markets its products directly and through a network of distributors to hospitals, healthcare organizations, and healthcare providers worldwide.

Orthofix Medical Inc. maintains a reputation as a global medical technology company committed to advancing patient care with innovative solutions for musculoskeletal healing. The company focuses on delivering exceptional experiences and life-changing solutions to patients worldwide. Strategic decisions, such as discontinuing certain product lines to concentrate on growth, demonstrate an adaptive market approach. The company has also seen a record number of placements for its 7D FLASH Navigation System in 2024. No specific negative events significantly impacting Orthofix Medical, Inc.'s brand reputation in the past year were found.

Institutional investors hold 91.65% of Orthofix Medical Inc.'s total shares, with hedge funds accounting for 35.8% of the total ownership. Major institutional shareholders include Engine Capital Management LP, Rubric Capital Management LP, BlackRock, Inc., Paradigm Capital Management Inc/ny, Juniper Investment Company, LLC, Vanguard Group Inc., Armistice Capital, Llc, Millennium Management Llc, and Dimensional Fund Advisors Lp. Insider ownership accounts for 25.88% of Orthofix Medical, with Engine Capital Management, LP also recognized as an insider holding 10.85%. Individual investors hold an 11% stake in the company.